Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Aude Fléchon et al.|The Lancet|2017Cited by 1.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Tibor Csőszi et al.|The Lancet Oncology|2021Cited by 645
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T. Tagawa, Petros Grivas, Arjun Vasant Balar et al.|Journal of Clinical Oncology|2021Cited by 530
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Stéphane Culine, Gwénaëlle Gravis et al.|European Urology|2020Cited by 246
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Dónal Landers, Danielle Carroll et al.|Nature Medicine|2021Cited by 115